MedPath

Potassium

Generic Name
Potassium
Drug Type
Small Molecule
Chemical Formula
K
CAS Number
7440-09-7
Unique Ingredient Identifier
RWP5GA015D
Background

Potassium is an essential nutrient, like Calcium and Magnesium. It was identified as a shortfall nutrient by the 2015-2020 Advisory Committee of Dietary Guidelines for Americans. Many conditions and diseases interfere with normal body potassium balance, and underconsumption of potassium is one example. Hypokalemia (low potassium) or hyperkalemia (high potassium) may result, manifesting as various signs and symptoms. Some examples of potassium-related complications include life-threatening arrhythmia, neuromuscular dysfunction, diarrhea, nausea, and vomiting.

Various pharmacological preparations have been formulated to replenish potassium. They are available in an assortment of tablet, injection, and other forms, depending on the setting and condition being treated. Potassium is often a key ingredient for intravenous fluids, given to patients in clinical settings for rehydration, nutrition, and replenishment of electrolytes. Examples of potassium formulations include potassium citrate, potassium chloride, and potassium with dextrose and sodium chloride.

Indication

General uses of potassium

Potassium is indicated to treat a variety of conditions. Firstly, it used to replenish potassium that has been depleted by conditions including but not limited to malabsorption, decreased intake, or excess sodium intake. The causes of potassium deficiency are numerous. The following indications for potassium are not comprehensive, but include the main indications for which this nutrient is used. Various products and preparations contain potassium.

Potassium chloride

Potassium chloride is one of the main preparations of potassium used in a clinical setting. The oral solution is indicated for the prevention and treatment of hypokalemia presenting with or without metabolic alkalosis, in patients who have failed conservative management with potassium-rich foods or diuretic dose titrations. The injection form of potassium chloride is indicated to replenish potassium in patients who are not feasible candidates for oral potassium. Highly concentrated potassium is intended for the treatment of potassium deficiency in fluid restricted individuals who cannot tolerate fluid volumes normally associated with injected potassium solutions that contain lower concentrations.

Finally, the extended-release tablet preparation of potassium chloride is used to treat hypokalemia with or without metabolic alkalosis, to treat digitalis intoxication, and to manage patients with hypokalemic familial periodic paralysis. It is also used in the prevention of hypokalemia in those who are at a high risk of negative clinical outcomes if hypokalemia occurs; patients on digitalis or those with cardiac arrhythmias would be at particular risk of negative outcomes.

Potassium chloride with dextrose and sodium chloride

This liquid preparation is is indicated in a clinical setting as a source of water, calories and electrolytes. Potassium acetate solution is meant as an alternative to potassium chloride, replenishing potassium and added to large volume infusion fluids for intravenous injection.

Potassium citrate

The potassium citrate preparation is used for the management of renal tubular acidosis (RTA) with calcium stones (nephrolithiasis); calcium oxalate stones by any cause, and uric acid nephrolithiasis (with or without calcium stones). This regimen also includes adequate water intake (leading to a urine out put of 2 L/day or more) and sodium restriction.

Associated Conditions
Caloric Intake, Electrolyte and fluid balance conditions, Hydration, Hypokalemia, Potassium

Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement

Phase 4
Recruiting
Conditions
AORTIC VALVE DISEASES
Thromboembolism
Interventions
First Posted Date
2020-02-06
Last Posted Date
2024-07-08
Lead Sponsor
Joon Bum Kim
Target Recruit Count
1300
Registration Number
NCT04258488
Locations
🇰🇷

Dong-A University Hospital, Busan, Korea, Republic of

🇰🇷

GangNeung Asan Hospital, Gangneung, Korea, Republic of

🇰🇷

Chonnam National University Hospital, Gwangju, Korea, Republic of

and more 8 locations

Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4

Phase 1
Completed
Conditions
Rheumatoid Arthritis
Interventions
First Posted Date
2020-01-29
Last Posted Date
2024-08-15
Lead Sponsor
R-Pharm International, LLC
Target Recruit Count
17
Registration Number
NCT04246762
Locations
🇧🇬

Comac Medical Ltd, Sofia, Bulgaria

🇲🇩

ICS ARENSIA Exploratory Medicine SRL, a daughter company of ARENSIA Exploratory Medicine GmbH,Republican Clinical Hospital, Chisinau, Moldova, Republic of

Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies

First Posted Date
2019-12-24
Last Posted Date
2021-04-08
Lead Sponsor
Xijing Hospital of Digestive Diseases
Target Recruit Count
240
Registration Number
NCT04209933
Locations
🇨🇳

Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China

A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection

First Posted Date
2019-12-13
Last Posted Date
2023-09-07
Lead Sponsor
Takeda
Target Recruit Count
510
Registration Number
NCT04198363
Locations
🇨🇳

The First People's Hospital of Foshan, Foshan, Guangdong, China

🇨🇳

Friendship Hospital, Capital Medical University, Beijing, Beijing, China

🇨🇳

Peking University Third Hospital, Beijing, Beijing, China

and more 26 locations

Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?

Phase 3
Completed
Conditions
Graves Disease
Interventions
First Posted Date
2019-09-06
Last Posted Date
2023-04-13
Lead Sponsor
Columbia University
Target Recruit Count
29
Registration Number
NCT04080505
Locations
🇺🇸

Columbia University Irving Medical Center, New York, New York, United States

Registration of Idarucizumab for Patients with IntraCranial Hemorrhage

First Posted Date
2019-08-20
Last Posted Date
2024-12-09
Lead Sponsor
University Hospital, Essen
Target Recruit Count
104
Registration Number
NCT04062097
Locations
🇩🇪

Klinikum Schön Klinik Bad Aibling SE & Co. KG, Bad Aibling, Germany

🇩🇪

Hochtaunuskliniken GmbH, Bad Homburg, Germany

🇩🇪

Rhön Klinikum Campus Bad Neustadt, Bad Neustadt An Der Saale, Germany

and more 30 locations

Prevention of Dysrhythmias on the Cardiac Intensive Care Unit - Does Maintenance of High-normal Serum Potassium Levels Matter

Phase 3
Completed
Conditions
Arrhythmias, Cardiac
Interventions
First Posted Date
2019-08-13
Last Posted Date
2024-11-05
Lead Sponsor
Barts & The London NHS Trust
Target Recruit Count
1684
Registration Number
NCT04053816
Locations
🇬🇧

Barts Health NHS Trust, London Borough of Sutton, London, United Kingdom

Randomized Controlled Trial to Study the Outcome of Intravenous Phosphate Supplementation in Live Donors Undergoing Hepatectomy for Living Donor Liver Transplantation (LDLT)

Phase 4
Completed
Conditions
Regeneration Liver
Complication, Postoperative
Interventions
First Posted Date
2019-07-19
Last Posted Date
2021-11-02
Lead Sponsor
Institute of Liver and Biliary Sciences, India
Target Recruit Count
130
Registration Number
NCT04026438
Locations
🇮🇳

Institute of Liver and Biliary Sciences, New Delhi, India

A Clinical Study to Assess the Effects of Various Dentifrice Technologies on Dentinal Hypersensitivity

Not Applicable
Completed
Conditions
Dentin Hypersensitivity
Interventions
Device: Dipotassium oxalate toothpaste
Drug: Stannous fluoride toothpaste
Drug: Sodium monofluorophosphate toothpaste
First Posted Date
2019-05-28
Last Posted Date
2020-10-30
Lead Sponsor
Procter and Gamble
Target Recruit Count
120
Registration Number
NCT03965039
Locations
🇺🇸

Silverstone Research Group, Las Vegas, Nevada, United States

Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant

Phase 3
Recruiting
Conditions
ST Segment Elevation Myocardial Infarction
Left Ventricular Thrombus
Interventions
First Posted Date
2018-12-05
Last Posted Date
2023-06-01
Lead Sponsor
RenJi Hospital
Target Recruit Count
280
Registration Number
NCT03764241
Locations
🇨🇳

Ren Ji Hospital Affliated to School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath